Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01194648
Other study ID # CDR0000684020
Secondary ID 9945
Status Recruiting
Phase N/A
First received September 2, 2010
Last updated April 18, 2018
Start date June 29, 2011
Est. completion date June 2029

Study information

Verified date April 2018
Source University College, London
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Prospective trials using hemi-ablation with high intensity focused ultrasound (HIFU) (Sonablate 500) have demonstrated feasibility, safety, and encouraging functional outcomes and early cancer control with 90% of men achieving trifecta status (no erectile dysfunction, leak-free pad-free continence, cancer control). However, these trials have involved small numbers of patients with men selected for good baseline function. A multi-centre prospective trial within a larger cohort of men that better represents the patient population with prostate cancer (external validity) is required.


Description:

Verification of a new therapy as favourable, or equivalent, in outcome to 'standard' care is ideally sought through comparison with another matched control group. Randomised controlled trials (RCTs) offer the best method for minimising systematic bias and revealing the true effect of an intervention or drug. However, RCTs involving treatments of localised prostate cancer have had a historically poor patient uptake, as the reference 'gold' standard of care is not known. In addition, RCTs are expensive to run and involve huge infra-structural support. A number of trials in the USA have been forced to close due to lack of recruitment. The ProStart trial in the UK has also had to close for the same reason. It has been acknowledged by the Food and Drug Agency in the USA that comparative randomized trials will be problematic in this area due to lack of physician and patient equipoise. A randomized trial may be feasible if a pragmatic design is adopted but prior to acceptance of such a design, the number of centres with expertise in this complex intervention (mp-MRI, TTPM, focal HIFU) will need to be increased.

Observational studies are a commonly used alternative to ascertain the effectiveness of a treatment. They are used to observe a treatment effect in a selected group of patients who are presumed to derive benefit from the treatment given. Although methodologically not as robust, and therefore prone to bias, they have some benefits over RCTs. The principal ones are those of enhanced external validity (many patients do not wished to be randomised and therefore refuse participation), and more rapid accrual compared to a randomised design. For this reasons, a single arm medium term follow-up cohort intervention study has been designed. At the time of writing the safety and tolerability aspects of focal therapy by HIFU are known as a result of the Phase I/II studies carried out at UCLH. The results have been presented and exist in the public domain in abstract form but have not yet been published (presented in tables above). These early studies were powered to detect a change in the proportion of men who could obtain an erection sufficient for penetration compared to their status prior to their treatment. The very low event rate for both erectile dysfunction and incontinence indicates that the 'proof of concept' has been demonstrated for focal therapy. Moreover, we can be relatively confident that, in expert hands, focal HIFU is safe. Therefore, a multi-centre study is now required involving a larger group of patients for the following reasons:

1. To evaluate medium term cancer control using histological parameters. Stage two of INDEX will evaluate conversion to radical and systemic therapies and link men to national databases to determine survival in 5 and 10 years.

2. To confirm that focal therapy can lead to low rates of genitourinary and rectal toxicity and minimal impact on quality of life within a large and more representative cohort of patients (greater precision around outcome measures).

3. To demonstrate that the skills (characterization through template prostate mapping and MRI as well as the treatment related skills) acquired by the team at UCLH are indeed transferable to other providers.

4. To calculate costs of care and to model potential cost-effectiveness in comparison to alternative therapies. If this single arm intervention study demonstrates acceptable outcomes to support the findings of the Phase I/II studies, it is anticipated that this preliminary study will lead onto a Phase III evaluation of focal therapy, prior to more widespread use of this technology.


Recruitment information / eligibility

Status Recruiting
Enrollment 354
Est. completion date June 2029
Est. primary completion date December 2028
Accepts healthy volunteers No
Gender Male
Age group N/A to 90 Years
Eligibility 1. Histologically proven prostate cancer on trans-rectal or transperineal template prostate biopsies.

2. Prostate biopsy (either TRUS or MRI Targeted or Template):

- TRUS biopsy: up to burden bilateral disease with maximum 3mm one biopsy on non-dominant side is allowable.

- MRI targeted and/or Template biopsy within 12 months of entry showing:

- unilateral disease minimum 3mm of Gleason 3+3 or any Gleason 3+4 or 4+3 but not exceeding Gleason 4+3 overall OR

- bilateral disease presence of clinically significant cancer on only one side (as determined by histological rules described above) Gleason =7 which is concordant with the MRI findings.

3. Stage T1-T2cN0M0 disease, as determined by local guidelines (radiological T3a permitted).

4. Serum PSA </=20ng/ml

5. Life expectancy of >/=10 years.

6. Signed informed consent by patient.

7. An understanding of the English language sufficient to understand

Study Design


Intervention

Other:
questionnaire administration

Procedure:
assessment of therapy complications

high-intensity focused ultrasound ablation

multiparametric magnetic resonance imaging

quality-of-life assessment

transperineal prostate biopsy

transrectal prostate biopsy


Locations

Country Name City State
United Kingdom University College London London England

Sponsors (1)

Lead Sponsor Collaborator
University College, London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Conversion to radical therapy and/or requiring systemic therapy and/or developing metastases and/or dying of prostate cancer To determine the proportion of men converting to radical therapy and/or requiring systemic therapy and/or developing metastases and/or dying of prostate cancer following focal therapy for localised prostate cancer using HIFU 5 years
Primary Conversion to radical therapy and/or requiring systemic therapy and/or developing metastases and/or dying of prostate cancer To determine the proportion of men converting to radical therapy and/or requiring systemic therapy and/or developing metastases and/or dying of prostate cancer following focal therapy for localised prostate cancer using HIFU 10 years
Secondary rate of erectile dysfunction The presence of severe erectile dysfunction at 12 months, as measured by the IIEF-5 questionnaire with or without the use of phosphodiesterase-5 inhibitors, in those with absence of severe erectile dysfunction at baseline 12 months
Secondary rate of erectile dysfunction The presence of severe erectile dysfunction at 24 months, as measured by the IIEF-5 questionnaire with or without the use of phosphodiesterase-5 inhibitors, in those with absence of severe erectile dysfunction at baseline 24 months
Secondary time to return of erectile function Time to return of erectile function (absence of severe ED on IIEF-15 questionnaire) 24 months
Secondary rate of urinary incontinence (pad free, leak free and pad-free alone) Presence of urinary incontinence (any pad usage plus any leakage of urine) as determined by the UCLA-EPIC urinary continence questionnaire, at 12 months, in those men with no urinary incontinence at baseline 12 months
Secondary rate of urinary incontinence (pad free, leak free and pad-free alone) Presence of urinary incontinence (any pad usage plus any leakage of urine) as determined by the UCLA-EPIC urinary continence questionnaire, at 24 months, in those men with no urinary incontinence at baseline 24 months
Secondary time to return of continence (pad free, leak free and pad-free alone) Time to return of urinary continence (as determined by UCLA-EPIC Urinary domain questionnaire) 24 months
Secondary rate of loss of ejaculation rate of loss of ejaculation (as determined by IIEF-15 questionnaire) 24 months
Secondary rate of loss of orgasm rate of loss of orgasm (as determined by IIEF-15 questionnaire) 24 months
Secondary rate of pain during intercourse rate of pain during intercourse (as determined by IIEF-15 questionnaire) 24 months
Secondary number of men using phosphodiesterase-5 inhibitors to maintain erectile function Need for phosphodiesterase-5 inhibitors to maintain erectile function sufficient for penetration up to 24 months 24 months
Secondary rate of lower urinary tract symptoms Grading of lower urinary tract symptoms as determined by IPSS scores 24 months
Secondary rate of bowel toxicity UCLA-EPIC Bowel Function Questionnaire 24 months
Secondary anxiety levels EQ-5D Quality of Life Questionnaire 24 months
Secondary general health related quality of life General and prostate health related quality of life measured using EQ-5D Quality of Life questionnaire 24 months
Secondary proportion of men achieving trifecta status at 12 months Achievement of trifecta status (no severe ED, pad-free leak-free continence, cancer control with absence of clinically significant cancer) at 12 months in those men with good baseline function 12months
Secondary proportion of men achieving trifecta status at 24 months Achievement of trifecta status (no severe ED, pad-free leak-free continence, cancer control with absence of clinically significant cancer) at 24 months in those men with good baseline function 24 months
Secondary rate of secondary prostate cancer intervention (prostatectomy, radiotherapy, androgen ablation, whole-gland HIFU or cryosurgery) rate of secondary prostate cancer intervention (prostatectomy, radiotherapy, androgen ablation, whole-gland HIFU or cryosurgery) 24 months
Secondary risk factors for failure defined as a) presence of any cancer and b) clinically significant cancer at study end risk factors for failure defined as a) presence of any cancer and b) clinically significant 24 months
Secondary biochemical (PSA) kinetics including determining the optimal biochemical definition of failure biochemical (PSA) kinetics including determining the optimal biochemical definition of 24 months
Secondary describe composite outcomes of failure describe composite outcomes of failure 24 months
Secondary Cost-effectiveness To determine the costs of treatment and model potential cost effectiveness using comparative cancer control and functional outcomes at 5 years compared to other cohort trials involving the management of localized prostate cancer 5years
Secondary Cost-effectiveness To determine the costs of treatment and model potential cost effectiveness using comparative cancer control and functional outcomes at 10 years compared to other cohort trials involving the management of localized prostate cancer 10 years
See also
  Status Clinical Trial Phase
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A